PREDICTIVE ONCOLOGY INC POAI 深 滬
等待開盤 07-18 09:30:00 美东时间
0.80
+0.017
+2.13%
華盛通- 最 高0.8199
- 今 開0.795
- 成交量 16.22万股
- 最 低 0.78
- 昨 收 0.7833
- 總市值 714.53万
- 52周最高 3.06
- 市盈率 靜 --
- 換手率 1.82%
- 52周最低 0.55
- 委 比 -27.12%
- 總股本 893.16万
- 歷史最高 170.00
- 量 比 1.86
- 振 幅 5.09%
- 歷史最低 0.55
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Predictive Oncology Secures $10M Funding To Drive U.S. And European Expansion Of ChemoFx And Fuel AI-Driven Drug Discovery
$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiativesDiscussions underway to expand adoption of ChemoFx in the U.S. and
07-15 21:02
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities
Predictive Oncology Inc. announced a $10 million securities purchase agreement with Yorkville Advisors Global to support expansion of its ChemoFx assay in the U.S. and Europe. ChemoFx, a live-cell tumor profiling assay, helps oncologists make personalized treatment decisions. The company also advances AI-driven drug discovery and biomarker efforts using its biobank of 150,000 tumor samples. Discussions with potential partners are underway to expa...
07-15 13:00
Predictive Oncology Faces Nasdaq Non-Compliance Notice
Predictive Oncology ( ($POAI) ) has issued an announcement. On July 8, 2025, Pr...
07-12 05:00
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
Predictive Oncology Inc. (NASDAQ: POAI) has entered into a $10 million standby equity purchase agreement (SEPA) with YA II PN, LTD, managed by Yorkville Advisors Global. The partnership provides flexible funding to advance the company's AI-driven drug discovery, biomarker discovery, and drug repurposing efforts. Predictive Oncology retains sole discretion over timing and amounts of stock sales, with no warrants or minimum use requirements. The co...
07-08 13:00
Predictive Oncology Develops 3D Organoid Models Exclusively For Labcorp, Including Human And Rat Model
Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE:LH), a global leader of innovative and
06-12 20:57
Court Denies Renovaro Motion for an Expedited Trial in July
Predictive Oncology Inc. (POAI) disputes Renovaro, Inc.'s (RENB) claims, asserting they are based on inaccurate allegations. The Delaware Court of Chancery rejected RENB's request for an expedited July trial, citing delays, and scheduled the trial for November 12-13, 2025. POAI aims to protect its rights in the upcoming court proceedings. The company specializes in AI-driven drug discovery for cancer treatment, using its PEDAL platform to predict...
05-27 12:35
Renovaro Receives Ruling To Expedite Trial In 2025 For Lawsuit It Filed On May 9, 2025, In Delaware Court Of Chancery Against Predictive Oncology Seeking To Enforce Binding Merger Agreement Executed On January 1, 2025
Renovaro Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025
05-22 23:11
Predictive Oncology shares are trading higher after the company reported a year-over-year increase in Q1 financial results.
Predictive Oncology shares are trading higher after the company reported a year...
05-15 20:54
CORRECTION: Predictive Oncology Q1 EPS $(0.34) Up From $(1.04) YoY, Sales $110.31K Up From $4.86K YoY
Predictive Oncology (NASDAQ:POAI) reported quarterly losses of $(0.34) per share. This is a 67.31 percent increase over losses of $(1.04) per share from the same period last year. The company reported $110.31 thousand
05-15 19:23
Renovaro says Predictive Oncology terminates merger transaction
Renovaro BioSciences (NASDAQ:RENB) has announced that it received an email from Predictive Oncology (NASDAQ:POAI) terminating the merger transaction. The company added, Renovaro's position is that POI...
04-04 22:49
